D
Pediatrix Medical Group, Inc.
MD
$13.99
$0.282.04%
D
Sell
2/24/2025Downgrade
Pediatrix Medical Group, Inc. (MD) was downgraded to D- from D on 2/24/2025 due to a major decline in the efficiency index and valuation index.
Pediatrix Medical Group, Inc. (MD) was downgraded to D- from D on 2/24/2025 due to a major decline in the efficiency index and valuation index.
D
Sell
9/27/2024Upgraded
Pediatrix Medical Group, Inc. (MD) was upgraded to D from D- on 9/27/2024 due to an increase in the volatility index and total return index.
Pediatrix Medical Group, Inc. (MD) was upgraded to D from D- on 9/27/2024 due to an increase in the volatility index and total return index.
D
Sell
9/12/2024Downgrade
Pediatrix Medical Group, Inc. (MD) was downgraded to D- from D on 9/12/2024 due to a decline in the volatility index.
Pediatrix Medical Group, Inc. (MD) was downgraded to D- from D on 9/12/2024 due to a decline in the volatility index.
D
Sell
8/26/2024Upgraded
Pediatrix Medical Group, Inc. (MD) was upgraded to D from D- on 8/26/2024 due to an increase in the volatility index and total return index.
Pediatrix Medical Group, Inc. (MD) was upgraded to D from D- on 8/26/2024 due to an increase in the volatility index and total return index.
D
Sell
8/7/2024Downgrade
Pediatrix Medical Group, Inc. (MD) was downgraded to D- from D on 8/7/2024 due to a significant decline in the valuation index, efficiency index and growth index. Net income declined 3,892.44% from $4.04M to -$153.03M, earnings per share declined from $0.0487 to -$1.84, and total capital declined 14.07% from $1.63B to $1.4B.
Pediatrix Medical Group, Inc. (MD) was downgraded to D- from D on 8/7/2024 due to a significant decline in the valuation index, efficiency index and growth index. Net income declined 3,892.44% from $4.04M to -$153.03M, earnings per share declined from $0.0487 to -$1.84, and total capital declined 14.07% from $1.63B to $1.4B.
D
Sell
2/7/2024Downgrade
Pediatrix Medical Group, Inc. (MD) was downgraded to D from D+ on 2/7/2024 due to a major decline in the growth index, total return index and volatility index. Earnings per share declined from $0.34 to $0.2591, EBIT declined 16.96% from $48.5M to $40.27M, and operating cash flow declined 10.24% from $89.05M to $79.94M.
Pediatrix Medical Group, Inc. (MD) was downgraded to D from D+ on 2/7/2024 due to a major decline in the growth index, total return index and volatility index. Earnings per share declined from $0.34 to $0.2591, EBIT declined 16.96% from $48.5M to $40.27M, and operating cash flow declined 10.24% from $89.05M to $79.94M.
D
Sell
9/11/2023Downgrade
Pediatrix Medical Group, Inc. (MD) was downgraded to D+ from C- on 9/11/2023 due to a decline in the volatility index.
Pediatrix Medical Group, Inc. (MD) was downgraded to D+ from C- on 9/11/2023 due to a decline in the volatility index.
C
Hold
8/25/2023Upgraded
Pediatrix Medical Group, Inc. (MD) was upgraded to C- from D+ on 8/25/2023 due to an increase in the volatility index, total return index and solvency index.
Pediatrix Medical Group, Inc. (MD) was upgraded to C- from D+ on 8/25/2023 due to an increase in the volatility index, total return index and solvency index.
D
Sell
8/4/2023Upgraded
Pediatrix Medical Group, Inc. (MD) was upgraded to D+ from D on 8/4/2023 due to a substantial increase in the efficiency index, growth index and valuation index. Operating cash flow increased 188.24% from -$100.92M to $89.05M, earnings per share increased from $0.17 to $0.34, and net income increased 99.08% from $14.21M to $28.28M.
Pediatrix Medical Group, Inc. (MD) was upgraded to D+ from D on 8/4/2023 due to a substantial increase in the efficiency index, growth index and valuation index. Operating cash flow increased 188.24% from -$100.92M to $89.05M, earnings per share increased from $0.17 to $0.34, and net income increased 99.08% from $14.21M to $28.28M.
D
Sell
11/10/2022Downgrade
Pediatrix Medical Group, Inc. (MD) was downgraded to D from D+ on 11/10/2022 due to a decline in the volatility index.
Pediatrix Medical Group, Inc. (MD) was downgraded to D from D+ on 11/10/2022 due to a decline in the volatility index.
D
Sell
10/26/2022Upgraded
Pediatrix Medical Group, Inc. (MD) was upgraded to D+ from D on 10/26/2022 due to an increase in the volatility index.
Pediatrix Medical Group, Inc. (MD) was upgraded to D+ from D on 10/26/2022 due to an increase in the volatility index.
D
Sell
10/11/2022Downgrade
Pediatrix Medical Group, Inc. (MD) was downgraded to D from D+ on 10/11/2022 due to a decline in the volatility index and total return index.
Pediatrix Medical Group, Inc. (MD) was downgraded to D from D+ on 10/11/2022 due to a decline in the volatility index and total return index.
D
Sell
8/31/2022Downgrade
Pediatrix Medical Group, Inc. (MD) was downgraded to D+ from C- on 8/31/2022 due to a decline in the volatility index and total return index.
Pediatrix Medical Group, Inc. (MD) was downgraded to D+ from C- on 8/31/2022 due to a decline in the volatility index and total return index.
C
Hold
8/9/2022Upgraded
Pediatrix Medical Group, Inc. (MD) was upgraded to C- from D+ on 8/9/2022 due to a significant increase in the growth index and volatility index. Earnings per share increased from -$0.2529 to $0.3184, operating cash flow increased 184.54% from -$97.48M to $82.41M, and EBIT increased 36.92% from $40.53M to $55.49M.
Pediatrix Medical Group, Inc. (MD) was upgraded to C- from D+ on 8/9/2022 due to a significant increase in the growth index and volatility index. Earnings per share increased from -$0.2529 to $0.3184, operating cash flow increased 184.54% from -$97.48M to $82.41M, and EBIT increased 36.92% from $40.53M to $55.49M.
D
Sell
8/2/2022Upgraded
Pediatrix Medical Group, Inc. (MD) was upgraded to D+ from D on 8/2/2022 due to an increase in the volatility index and total return index.
Pediatrix Medical Group, Inc. (MD) was upgraded to D+ from D on 8/2/2022 due to an increase in the volatility index and total return index.
D
Sell
4/29/2022Downgrade
MEDNAX, Inc. (MD) was downgraded to D from D+ on 4/29/2022 due to a large decline in the growth index, valuation index and volatility index. Operating cash flow declined 320.37% from $44.24M to -$97.48M, earnings per share declined from $0.5509 to -$0.2529, and EBIT declined 42.97% from $71.06M to $40.53M.
MEDNAX, Inc. (MD) was downgraded to D from D+ on 4/29/2022 due to a large decline in the growth index, valuation index and volatility index. Operating cash flow declined 320.37% from $44.24M to -$97.48M, earnings per share declined from $0.5509 to -$0.2529, and EBIT declined 42.97% from $71.06M to $40.53M.
D
Sell
3/21/2022Downgrade
MEDNAX, Inc. (MD) was downgraded to D+ from C- on 3/21/2022 due to a decline in the total return index.
MEDNAX, Inc. (MD) was downgraded to D+ from C- on 3/21/2022 due to a decline in the total return index.
C
Hold
3/4/2022Upgraded
MEDNAX, Inc. (MD) was upgraded to C- from D+ on 3/4/2022 due to a significant increase in the valuation index, solvency index and efficiency index. Net income increased 54.3% from $30.8M to $47.52M, debt to equity declined from 1.21 to 1.13, and total capital increased 2.7% from $1.91B to $1.96B.
MEDNAX, Inc. (MD) was upgraded to C- from D+ on 3/4/2022 due to a significant increase in the valuation index, solvency index and efficiency index. Net income increased 54.3% from $30.8M to $47.52M, debt to equity declined from 1.21 to 1.13, and total capital increased 2.7% from $1.91B to $1.96B.
D
Sell
11/3/2021Upgraded
MEDNAX, Inc. (MD) was upgraded to D+ from D on 11/3/2021 due to a major increase in the efficiency index and valuation index. Total capital increased 2.36% from $1.87B to $1.91B.
MEDNAX, Inc. (MD) was upgraded to D+ from D on 11/3/2021 due to a major increase in the efficiency index and valuation index. Total capital increased 2.36% from $1.87B to $1.91B.
D
Sell
8/6/2021Downgrade
MEDNAX, Inc. (MD) was downgraded to D from D+ on 8/6/2021 due to a decline in the valuation index.
MEDNAX, Inc. (MD) was downgraded to D from D+ on 8/6/2021 due to a decline in the valuation index.
D
Sell
5/10/2021Upgraded
MEDNAX, Inc. (MD) was upgraded to D+ from D on 5/10/2021 due to a substantial increase in the total return index, volatility index and solvency index. Debt to equity declined from 2.35 to 1.33.
MEDNAX, Inc. (MD) was upgraded to D+ from D on 5/10/2021 due to a substantial increase in the total return index, volatility index and solvency index. Debt to equity declined from 2.35 to 1.33.
D
Sell
11/10/2020Upgraded
MEDNAX, Inc. (MD) was upgraded to D from D- on 11/10/2020 due to a noticeable increase in the growth index, total return index and volatility index. Earnings per share increased from -$8.1075 to -$0.4894, total revenue increased 56.23% from $294.84M to $460.64M, and EBIT increased 48.41% from $36.89M to $54.75M.
MEDNAX, Inc. (MD) was upgraded to D from D- on 11/10/2020 due to a noticeable increase in the growth index, total return index and volatility index. Earnings per share increased from -$8.1075 to -$0.4894, total revenue increased 56.23% from $294.84M to $460.64M, and EBIT increased 48.41% from $36.89M to $54.75M.
D
Sell
5/5/2020Downgrade
MEDNAX, Inc. (MD) was downgraded to D- from D on 5/5/2020 due to a decline in the total return index and efficiency index. Total capital declined 5.35% from $3.51B to $3.32B.
MEDNAX, Inc. (MD) was downgraded to D- from D on 5/5/2020 due to a decline in the total return index and efficiency index. Total capital declined 5.35% from $3.51B to $3.32B.
D
Sell
1/16/2020Upgraded
MEDNAX, Inc. (MD) was upgraded to D from D- on 1/16/2020 due to an increase in the total return index.
MEDNAX, Inc. (MD) was upgraded to D from D- on 1/16/2020 due to an increase in the total return index.
D
Sell
11/5/2019Downgrade
MEDNAX, Inc. (MD) was downgraded to D- from D on 11/5/2019 due to a significant decline in the efficiency index, solvency index and total return index. Net income declined 15,132.46% from -$8.25M to -$1.26B, debt to equity increased from 0.77 to 1.33, and total capital declined 28.42% from $4.9B to $3.51B.
MEDNAX, Inc. (MD) was downgraded to D- from D on 11/5/2019 due to a significant decline in the efficiency index, solvency index and total return index. Net income declined 15,132.46% from -$8.25M to -$1.26B, debt to equity increased from 0.77 to 1.33, and total capital declined 28.42% from $4.9B to $3.51B.
D
Sell
5/7/2019Downgrade
MEDNAX, Inc. (MD) was downgraded to D from D+ on 5/7/2019 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.6764 to -$2.8076, net income declined 503.35% from $60.21M to -$242.87M, and operating cash flow declined 144.53% from $127.59M to -$56.82M.
MEDNAX, Inc. (MD) was downgraded to D from D+ on 5/7/2019 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.6764 to -$2.8076, net income declined 503.35% from $60.21M to -$242.87M, and operating cash flow declined 144.53% from $127.59M to -$56.82M.
D
Sell
12/4/2018Downgrade
MEDNAX, Inc. (MD) was downgraded to D+ from C- on 12/4/2018 due to a decline in the volatility index, growth index and solvency index. Earnings per share declined from $0.85 to $0.72, EBIT declined 15.17% from $128.68M to $109.16M, and debt to equity increased from 0.59 to 0.67.
MEDNAX, Inc. (MD) was downgraded to D+ from C- on 12/4/2018 due to a decline in the volatility index, growth index and solvency index. Earnings per share declined from $0.85 to $0.72, EBIT declined 15.17% from $128.68M to $109.16M, and debt to equity increased from 0.59 to 0.67.
C
Hold
4/30/2018Downgrade
MEDNAX, Inc. (MD) was downgraded to C- from C on 4/30/2018 due to a decline in the volatility index and total return index.
MEDNAX, Inc. (MD) was downgraded to C- from C on 4/30/2018 due to a decline in the volatility index and total return index.
C
Hold
2/21/2018Upgraded
MEDNAX, Inc. (MD) was upgraded to C from C- on 2/21/2018 due to an increase in the volatility index, valuation index and total return index.
MEDNAX, Inc. (MD) was upgraded to C from C- on 2/21/2018 due to an increase in the volatility index, valuation index and total return index.
C
Hold
1/2/2018Upgraded
MEDNAX, Inc. (MD) was upgraded to C- from D+ on 1/2/2018 due to an increase in the total return index.
MEDNAX, Inc. (MD) was upgraded to C- from D+ on 1/2/2018 due to an increase in the total return index.
D
Sell
10/6/2017Downgrade
MEDNAX, Inc. (MD) was downgraded to D+ from C- on 10/6/2017 due to a decline in the total return index, volatility index and efficiency index. Total capital declined 1.14% from $4.66B to $4.61B.
MEDNAX, Inc. (MD) was downgraded to D+ from C- on 10/6/2017 due to a decline in the total return index, volatility index and efficiency index. Total capital declined 1.14% from $4.66B to $4.61B.
C
Hold
7/25/2017Downgrade
MEDNAX, Inc. (MD) was downgraded to C- from C on 7/25/2017 due to a noticeable decline in the total return index, volatility index and valuation index.
MEDNAX, Inc. (MD) was downgraded to C- from C on 7/25/2017 due to a noticeable decline in the total return index, volatility index and valuation index.
C
Hold
5/10/2017Downgrade
MEDNAX, Inc. (MD) was downgraded to C from C+ on 5/10/2017 due to a noticeable decline in the total return index, volatility index and growth index. Operating cash flow declined 116.62% from $130.95M to -$21.76M, earnings per share declined from $0.8364 to $0.59, and EBIT declined 25.73% from $142.78M to $106.04M.
MEDNAX, Inc. (MD) was downgraded to C from C+ on 5/10/2017 due to a noticeable decline in the total return index, volatility index and growth index. Operating cash flow declined 116.62% from $130.95M to -$21.76M, earnings per share declined from $0.8364 to $0.59, and EBIT declined 25.73% from $142.78M to $106.04M.
C
Hold
3/24/2017Downgrade
MEDNAX, Inc. (MD) was downgraded to C+ from B- on 3/24/2017 due to a decline in the total return index, volatility index and solvency index.
MEDNAX, Inc. (MD) was downgraded to C+ from B- on 3/24/2017 due to a decline in the total return index, volatility index and solvency index.
B
Buy
3/7/2017Upgraded
MEDNAX, Inc. (MD) was upgraded to B- from C+ on 3/7/2017 due to an increase in the total return index, volatility index and solvency index. Debt to equity declined from 0.67 to 0.62.
MEDNAX, Inc. (MD) was upgraded to B- from C+ on 3/7/2017 due to an increase in the total return index, volatility index and solvency index. Debt to equity declined from 0.67 to 0.62.
C
Hold
2/6/2017Downgrade
MEDNAX, Inc. (MD) was downgraded to C+ from B- on 2/6/2017 due to a decline in the volatility index, valuation index and total return index.
MEDNAX, Inc. (MD) was downgraded to C+ from B- on 2/6/2017 due to a decline in the volatility index, valuation index and total return index.
B
Buy
12/8/2016Upgraded
MEDNAX, Inc. (MD) was upgraded to B- from C+ on 12/8/2016 due to an increase in the volatility index, total return index and valuation index.
MEDNAX, Inc. (MD) was upgraded to B- from C+ on 12/8/2016 due to an increase in the volatility index, total return index and valuation index.
C
Hold
10/27/2016Downgrade
MEDNAX, Inc. (MD) was downgraded to C+ from B- on 10/27/2016 due to a decline in the volatility index and total return index.
MEDNAX, Inc. (MD) was downgraded to C+ from B- on 10/27/2016 due to a decline in the volatility index and total return index.
B
Buy
7/29/2016Upgraded
MEDNAX, Inc. (MD) was upgraded to B- from C+ on 7/29/2016 due to a major increase in the growth index, total return index and volatility index. Operating cash flow increased 553.23% from -$33.04M to $149.74M, earnings per share increased from $0.73 to $0.89, and EBIT increased 18.96% from $124.23M to $147.79M.
MEDNAX, Inc. (MD) was upgraded to B- from C+ on 7/29/2016 due to a major increase in the growth index, total return index and volatility index. Operating cash flow increased 553.23% from -$33.04M to $149.74M, earnings per share increased from $0.73 to $0.89, and EBIT increased 18.96% from $124.23M to $147.79M.
C
Hold
4/20/2016Downgrade
MEDNAX, Inc. (MD) was downgraded to C+ from B- on 4/20/2016 due to a decline in the total return index, volatility index and valuation index.
MEDNAX, Inc. (MD) was downgraded to C+ from B- on 4/20/2016 due to a decline in the total return index, volatility index and valuation index.
B
Buy
3/11/2016Downgrade
MEDNAX, Inc. (MD) was downgraded to B- from B on 3/11/2016 due to a significant decline in the growth index, volatility index and total return index. Operating cash flow declined 39.5% from $172.12M to $104.14M, and EBIT declined 0.11% from $151.13M to $150.96M.
MEDNAX, Inc. (MD) was downgraded to B- from B on 3/11/2016 due to a significant decline in the growth index, volatility index and total return index. Operating cash flow declined 39.5% from $172.12M to $104.14M, and EBIT declined 0.11% from $151.13M to $150.96M.
B
Buy
2/4/2016Downgrade
MEDNAX, Inc. (MD) was downgraded to B from B+ on 2/4/2016 due to a large decline in the volatility index and total return index.
MEDNAX, Inc. (MD) was downgraded to B from B+ on 2/4/2016 due to a large decline in the volatility index and total return index.
B
Buy
1/5/2016Downgrade
MEDNAX, Inc. (MD) was downgraded to B+ from A- on 1/5/2016 due to a decline in the total return index and volatility index.
MEDNAX, Inc. (MD) was downgraded to B+ from A- on 1/5/2016 due to a decline in the total return index and volatility index.
A
Buy
11/20/2015Downgrade
MEDNAX, Inc. (MD) was downgraded to A- from A on 11/20/2015 due to a major decline in the volatility index, total return index and solvency index. The quick ratio declined from 1.45 to 1.18.
MEDNAX, Inc. (MD) was downgraded to A- from A on 11/20/2015 due to a major decline in the volatility index, total return index and solvency index. The quick ratio declined from 1.45 to 1.18.
A
Buy
7/31/2015Upgraded
MEDNAX, Inc. (MD) was upgraded to A from A- on 7/31/2015 due to a major increase in the growth index. Earnings per share increased from $0.72 to $0.9, EBIT increased 22.76% from $114.82M to $140.96M, and total revenue increased 5.82% from $639.4M to $676.59M.
MEDNAX, Inc. (MD) was upgraded to A from A- on 7/31/2015 due to a major increase in the growth index. Earnings per share increased from $0.72 to $0.9, EBIT increased 22.76% from $114.82M to $140.96M, and total revenue increased 5.82% from $639.4M to $676.59M.
A
Buy
5/1/2015Downgrade
MEDNAX, Inc. (MD) was downgraded to A- from A on 5/1/2015 due to a large decline in the growth index, solvency index and valuation index. Operating cash flow declined 130.02% from $178.81M to -$53.68M, debt to equity increased from 0.25 to 0.42, and earnings per share declined from $0.8917 to $0.72.
MEDNAX, Inc. (MD) was downgraded to A- from A on 5/1/2015 due to a large decline in the growth index, solvency index and valuation index. Operating cash flow declined 130.02% from $178.81M to -$53.68M, debt to equity increased from 0.25 to 0.42, and earnings per share declined from $0.8917 to $0.72.
A
Buy
12/30/2014Upgraded
MEDNAX, Inc. (MD) was upgraded to A from A- on 12/30/2014 due to a noticeable increase in the total return index and volatility index.
MEDNAX, Inc. (MD) was upgraded to A from A- on 12/30/2014 due to a noticeable increase in the total return index and volatility index.
A
Buy
11/28/2014Upgraded
MEDNAX, Inc. (MD) was upgraded to A- from B+ on 11/28/2014 due to an increase in the volatility index.
MEDNAX, Inc. (MD) was upgraded to A- from B+ on 11/28/2014 due to an increase in the volatility index.
B
Buy
10/30/2014Upgraded
MEDNAX, Inc. (MD) was upgraded to B+ from B on 10/30/2014 due to an increase in the volatility index.
MEDNAX, Inc. (MD) was upgraded to B+ from B on 10/30/2014 due to an increase in the volatility index.
B
Buy
10/1/2014Downgrade
MEDNAX, Inc. (MD) was downgraded to B from B+ on 10/1/2014 due to a decline in the volatility index.
MEDNAX, Inc. (MD) was downgraded to B from B+ on 10/1/2014 due to a decline in the volatility index.
B
Buy
8/7/2014Downgrade
MEDNAX, Inc. (MD) was downgraded to B+ from A- on 8/7/2014 due to a large decline in the volatility index, total return index and solvency index. The quick ratio declined from 1.54 to 1.34.
MEDNAX, Inc. (MD) was downgraded to B+ from A- on 8/7/2014 due to a large decline in the volatility index, total return index and solvency index. The quick ratio declined from 1.54 to 1.34.
NYSE
03/14/2025 12:51PM Eastern
Quotes delayed
